Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus type II, with conflicting results.
Differences in baseline body mass index ( BMI ) of patients may be able to explain the observed differences in the results.
A study was designed to evaluate the effect of cinnamon supplementation on anthropometric, glycemic and lipid outcomes of patients with diabetes mellitus type II based on their baseline BMI.
The study was designed as a triple-blind placebo-controlled randomized clinical trial, using a parallel design.
One hundred and forty patients referred to Diabetes Clinic of Yazd University of Medical Sciences with diagnosis of diabetes mellitus type II were randomly assigned in four groups: cinnamon ( BMI greater than or equal to 27, BMI less than 27 ) and placebo ( BMI greater than or equal to 27, BMI less than 27 ).
Patients received cinnamon bark powder or placebo in 500 mg capsules twice daily for 3 months.
Anthropometric, glycemic and lipid outcomes were measured before and after the intervention.
Cinnamon supplementation led to improvement of all anthropometric ( BMI, body fat, and visceral fat ), glycemic ( fasting plasma glucose, 2hpp, hemoglobin A1c [ HbA1C ], fasting insulin, and insulin resistance ), and lipids ( cholesterol total, LDL cholesterol and HDL cholesterol ) outcomes ( except for triglycerides level ).
All observed changes ( except for cholesterol total and LDL cholesterol ) were significantly more prominent in patients with higher baseline BMI ( BMI greater than or equal to 27 ).
In conclusion, based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
These benefits are significantly more prominent in patients with higher baseline BMI. ( Xagena )
Zare R et al, Clin Nutr 2018;doi:10.1016/j.clnu.2018.03.003.